Teleflex Inc Stock Research

Market Summary

USD232.22+6.73

Market Closed

2.98%

TFX Alerts

Big fall in earnings (Y/Y)

TFX Stock Price

TFX RSI Chart

TFX Valuation

Market Cap

10.9B

Price/Earnings (Trailing)

Price/Sales (Trailing)

3.9

EV/EBITDA

18.71

Price/Free Cashflow

41.32

TFX Price/Sales (Trailing)

TFX Profitability

EBT Margin

15.98%

Return on Equity

9.03%

Return on Assets

5.24%

Free Cashflow Yield

2.42%

TFX Fundamentals

TFX Revenue

Revenue (TTM)

2.8B

Revenue Y/Y

-0.51%

Revenue Q/Q

10.37%

TFX Earnings

Earnings (TTM)

363.1M

Earnings Y/Y

-38.64%

Earnings Q/Q

-22.87%

Price Action

52 Week Range

182.37355.24

(Low)(High)

Last 7 days

-0.9%

Last 30 days

-8.3%

Last 90 days

-9.8%

Trailing 12 Months

-32.5%

TFX Financial Health

Current Ratio

2.43

Debt/Equity

0.48

Debt/Cashflow

0.26

TFX Investor Care

Dividend Yield

0.59%

Dividend/Share (TTM)

1.36

Shares Dilution (1Y)

0.21%

Diluted EPS (TTM)

7.68

Peers (Alternatives to Teleflex)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
SYK	104.1B	18.4B	2.26%	8.00%	44.16	5.64	7.84%	18.25%
ISRG	84.2B	6.2B	-4.47%	-13.27%	63.66	13.53	8.97%	-22.43%
BSX	69.1B	12.7B	0.59%	12.45%	99.06	5.45	6.68%	-32.95%
BDX	67.4B	19.0B	-5.16%	-6.78%	41.86	3.55	-0.43%	-8.78%
EW	49.8B	5.4B	2.41%	-25.12%	32.74	9.26	2.86%	1.25%
MID-CAP
SWAV	7.2T	489.7M	9.34%	31.15%	82.2K	16.8K	106.51%	2464.23%
PEN	10.2B	847.1M	-3.64%	34.52%	-5.1K	12.05	13.32%	-137.89%
GMED	5.2B	1.0B	-11.64%	-20.31%	30.19	5.09	6.76%	24.45%
IRTC	3.5B	410.9M	4.51%	-3.13%	-29.82	8.43	27.29%	-14.60%
TNDM	2.7B	801.2M	1.13%	-58.87%	-28.25	3.34	14.00%	-707.69%
SMALL-CAP
SILK	1.7B	138.6M	-15.68%	29.18%	-30.43	12.07	36.62%	-10.44%
ATEC	1.6B	350.9M	10.38%	49.06%	-10.84	4.7	44.26%	-5.42%
AVNS	1.3B	820.0M	-8.35%	-12.22%	25.89	1.59	10.13%	701.59%
CSII	828.4M	239.8M	0.30%	1.49%	-21.88	3.45	-4.74%	-31.15%

Financials for Teleflex

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-0.1%	2,791	2,795	2,808	2,817	2,810
Gross Profit	0.2%	1,531	1,529	1,543	1,551	1,550
S&GA Expenses	0.7%	864	858	854	861	860
R&D Expenses	4.7%	154	147	141	137	131
EBITDA	-4.6%	567	594	705	853	-
EBITDA Margin	-4.5%	0.20*	0.21*	0.25*	0.30*	-
Earnings Before Taxes	-7.1%	446	480	590	566	559
EBT Margin	-6.9%	0.16*	0.17*	0.21*	0.20*	-
Interest Expenses	14.9%	54.00	47.00	46.00	51.00	57.00
Net Income	-12.0%	363	413	510	488	485
Net Income Margin	-11.9%	0.13*	0.15*	0.18*	0.17*	-
Free Cahsflow	-29.5%	264	374	422	538	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	2.5%	6,928	6,758	6,732	6,873	6,872
Current Assets	-3.3%	1,411	1,459	1,385	1,494	1,429
Cash Equivalents	-26.5%	292	397	308	467	445
Inventory	9.1%	579	530	511	491	478
Net PPE	5.9%	447	422	429	436	444
Goodwill	3451.8%	2,537	71.00	2,461	2,493	2,504
Liabilities	1.5%	2,906	2,863	2,879	3,078	3,117
Current Liabilities	-4.8%	581	611	610	656	680
Long Term Debt	-	1,850	-	-	-	-
LT Debt, Current	-	110	-	-	-	-
LT Debt, Non Current	1.9%	1,624	1,594	1,606	1,741	1,740
Shareholder's Equity	3.3%	4,022	3,895	3,853	3,796	3,755
Retained Earnings	8.5%	3,817	3,518	-	-	-
Additional Paid-In Capital	3.2%	715	693	-	-	-
Accumulated Depreciation	-	558	-	-	-	-
Shares Outstanding	0.0%	47.00	47.00	47.00	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-23.2%	343	446	489	603	652
Share Based Compensation	6.0%	27.00	26.00	24.00	23.00	23.00
Cashflow From Investing	-280.4%	-259	-68.20	144	165	157
Cashflow From Financing	47.7%	-217	-415	-649	-605	-715
Dividend Payments	0.0%	64.00	64.00	64.00	64.00	64.00

Risks for TFX

What is the probability of a big loss on TFX?

47.3%

Probability that Teleflex stock will be more than 20% underwater in next one year

44.6%

Probability that Teleflex stock will be more than 30% underwater in next one year.

12.7%

Probability that Teleflex stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TFX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Teleflex was unfortunately bought at previous high price.

Drawdowns

Returns for TFX

Cumulative Returns on TFX

11.5%

10-Year Cumulative Returns

6.9%

7-Year Cumulative Returns

-2.7%

5-Year Cumulative Returns

-10.5%

3-Year Cumulative Returns

What are the long-term rolling returns for TFX?

FIve years rolling returns for Teleflex.

Annualized Returns

Which funds bought or sold TFX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	added	71.00	2,416,470	4,575,470	-%
2023-03-10	MATHER GROUP, LLC.	new	-	220,174	220,174	-%
2023-03-06	Rockefeller Capital Management L.P.	added	39.49	231,000	548,000	-%
2023-02-28	Voya Investment Management LLC	added	2.92	897,835	4,158,840	0.01%
2023-02-24	SRS Capital Advisors, Inc.	added	0.2	666,114	3,425,110	0.47%
2023-02-24	NATIXIS	added	108	958,682	1,563,680	0.01%
2023-02-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	added	3.31	1,304,000	5,964,000	0.06%
2023-02-22	CVA Family Office, LLC	new	-	1,248	1,248	-%
2023-02-21	NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC	reduced	-15.61	15,956	366,956	0.01%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	added	0.48	21,596	104,596	-%

Latest Funds Activity

Are funds buying TFX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own TFX

No. of Funds

TFX Alerts

Big fall in earnings (Y/Y)

Teleflex News

Schedule 13G FIlings of Teleflex

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	t. rowe price investment management, inc.	18.4%	8,633,473	SC 13G/A
Feb 09, 2023	vanguard group inc	11.56%	5,420,563	SC 13G/A
Feb 06, 2023	wellington management group llp	6.59%	3,092,719	SC 13G/A
Feb 03, 2023	blackrock inc.	8.5%	3,969,361	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	13.8%	6,494,778	SC 13G/A
Feb 10, 2022	vanguard group inc	10.81%	5,063,204	SC 13G/A
Feb 04, 2022	wellington management group llp	7.11%	3,331,136	SC 13G/A
Jan 27, 2022	blackrock inc.	10.4%	4,856,339	SC 13G/A
Jan 25, 2022	blackrock inc.	10.4%	4,856,339	SC 13G/A
Sep 10, 2021	price t rowe associates inc /md/	15.6%	7,305,896	SC 13G/A

TFX Fair Value

Teleflex fair value in different scenarios

The table shows the Fair Value estimates for Teleflex for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	- -	- -	- -	- -	- -
Current Inflation	111.74 -51.88%	132.26 -43.05%	186.20 -19.82%	248.04 6.81%	298.42 28.51%
Very High Inflation	- -	- -	- -	- -	- -

Historical Teleflex Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Teleflex

View All Filings

Date Filed	Form Type	Document
Mar 10, 2023	PRE 14A	PRE 14A
Feb 28, 2023	4	Insider Trading
Feb 28, 2023	4	Insider Trading
Feb 28, 2023	4	Insider Trading
Feb 28, 2023	4	Insider Trading
Feb 28, 2023	4	Insider Trading
Feb 28, 2023	4	Insider Trading
Feb 28, 2023	4	Insider Trading
Feb 23, 2023	10-K	Annual Report
Feb 23, 2023	8-K	Current Report

Latest Insider Trading transactions for TFX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-28	POWELL THOMAS E	acquired	-	-	2,357	executive vice president & cfo
2023-02-28	Winters James	acquired	-	-	912	corp vp, mfg and supply
2023-02-28	Kelly Liam	acquired	-	-	5,050	chairman, president & ceo
2023-02-28	Hicks Cameron P	acquired	-	-	906	corp. vp & chief hr officer
2023-02-28	Logue Daniel V.	acquired	-	-	1,139	cvp, general counsel & secty
2023-02-28	Deren John	acquired	-	-	414	corp. vp & cao
2023-02-28	White Jay	acquired	-	-	1,347	cvp & pres, global commercial
2023-02-25	White Jay	sold (taxes)	-31,749	235	-135	cvp & pres, global commercial
2023-02-25	Hicks Cameron P	sold (taxes)	-31,514	235	-134	corp. vp & chief hr officer
2023-02-25	POWELL THOMAS E	sold (taxes)	-127,468	235	-542	executive vice president & cfo

About Teleflex

Liam J. Kelly

www.teleflex.com

14000

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

TFX Income Statement

2022-12-31

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net revenues	$ 2,791,041	$ 2,809,563	$ 2,537,156
Cost of goods sold	1,259,954	1,259,961	1,212,282
Gross profit	1,531,087	1,549,602	1,324,874
Selling, general and administrative expenses	863,748	860,085	743,568
Research and development expenses	153,819	130,841	119,747
Restructuring and impairment charges	20,299	21,738	38,491
Gain on sale of assets and business	(6,504)	(91,157)	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	499,725	628,095	423,068
Interest expense	54,264	56,969	66,494
Interest income	(912)	(1,328)	(1,158)
Loss on extinguishment of debt	454	12,986	0
Income from continuing operations before taxes	445,919	559,468	357,732
Taxes on income from continuing operations	83,003	74,349	21,931
Income from continuing operations	362,916	485,119	335,801
Operating income (loss) from discontinued operations	260	331	(621)
Taxes (benefit) on operating loss from discontinued operations	37	76	(144)
Income (loss) from discontinued operations	223	255	(477)
Net income	$ 363,139	$ 485,374	$ 335,324
Basic:
Income from continuing operations (in dollars per share)	$ 7.74	$ 10.37	$ 7.22
Income (loss) from discontinued operations (in dollars per share)	0	0.01	(0.01)
Net income (in dollars per share)	7.74	10.38	7.21
Diluted:
Income from continuing operations (in dollars per share)	7.67	10.23	7.10
Income (loss) from discontinued operations (in dollars per share)	0.01	0	(0.01)
Net income (loss), diluted (in dollar per share)	$ 7.68	$ 10.23	$ 7.09
Weighted average shares outstanding:
Basic (in shares)	46,898	46,774	46,488
Diluted (in shares)	47,309	47,427	47,287

TFX Balance Sheet

2022-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 292,034	$ 445,084
Accounts receivable, net	408,834	383,569
Inventories	578,507	477,643
Prepaid expenses and other current assets	125,084	117,277
Prepaid taxes	6,524	5,545
Total current assets	1,410,983	1,429,118
Property, plant and equipment, net	447,205	443,758
Operating lease assets	131,211	129,653
Goodwill	2,536,730	2,504,202
Intangibles assets, net	2,306,165	2,289,067
Deferred tax assets	6,402	6,820
Other assets	89,367	69,104
Total assets	6,928,063	6,871,722
Current liabilities
Current borrowings	87,500	110,000
Accounts payable	126,807	118,236
Accrued expenses	140,644	163,441
Payroll and benefit-related liabilities	133,092	143,657
Accrued interest	5,332	5,209
Income taxes payable	24,736	83,943
Other current liabilities	63,381	55,633
Total current liabilities	581,492	680,119
Long-term borrowings	1,624,023	1,740,102
Deferred tax liabilities	388,886	370,124
Pension and postretirement benefit liabilities	31,394	45,185
Noncurrent liability for uncertain tax positions	5,805	8,646
Noncurrent operating lease liabilities	120,437	116,033
Other liabilities	154,058	156,765
Total liabilities	2,906,095	3,116,974
Commitments and contingencies
Shareholders’ equity
Common shares, $1 par value Issued: 2022 — 47,957 shares; 2021 — 47,929 shares	47,957	47,929
Additional paid-in capital	715,118	693,090
Retained earnings	3,817,304	3,517,954
Accumulated other comprehensive loss	(403,522)	(346,959)
Shareholders equity before treasury stock, total	4,176,857	3,912,014
Less: Treasury stock, at cost	154,889	157,266
Total shareholders' equity	4,021,968	3,754,748
Total liabilities and shareholders' equity	$ 6,928,063	$ 6,871,722